Testosterone Use in Men and Its Effects on Bone Health. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Michal J. Tracz,
Kostandinos Sideras,
Enrique R. Boloña,
Rudy M. Haddad,
Cassie C. Kennedy,
Maria V. Uraga,
Sean M. Caples,
Patricia J. Erwin and
Victor M. Montori
Knowledge and Encounter Research Unit, Department of Medicine (M.J.T., K.S., E.R.B., R.M.H., C.C.K., M.V.U., S.M.C., P.J.E., V.M.M.); Mayo Library (P.J.E.); and Division of Endocrinology, Department of Medicine (V.M.M.), Mayo Clinic College of Medicine, Rochester, Minnesota 55905
Address all correspondence and requests for reprints to: Victor M. Montori, D.MSc., Mayo Clinic, W18A, 200 First Street SW, Rochester, Minnesota 55905. E-mail: montori.victor{at}mayo.edu.
Context: Androgen-deficient men are at increased risk of osteoporosis.The extent to which testosterone can prevent and treat osteoporosisin men remains unclear.
Objective and Design: We performed a systematic review and meta-analysisof randomized placebo-controlled trials in men to estimate theeffect of testosterone use on bone health outcomes.
Data Sources: The review encompassed librarian-designed searchstrategies using MEDLINE (1966 to March 2005), EMBASE (1988to March 2005), and Cochrane CENTRAL (inception to March 2005);a review of reference lists from included studies; and contentexpert files.
Data Collection: Independently and in duplicate, we assessedthe methodological quality of the eligible trials and collecteddata on bone mineral density and bone fractures at the longestpoint of complete follow-up.
Data Synthesis: We included eight trials enrolling 365 patients.Two trials followed patients for more than 1 yr. Meta-analysisof these trials showed that, compared with placebo, im testosteronewas associated with an 8% (95% confidence interval, 4%, 13%)gain in lumbar bone mineral density and transdermal testosteronehad no significant impact. Testosterone use was associated witha nonsignificant 4% (95% confidence interval, 2%, 9%)gain in femoral neck bone mineral density with unexplained differencesin results across trials (26% of these differences were notexplained by chance alone). No trials measured or reported theeffect of testosterone on fractures.
Conclusions: Intramuscular testosterone moderately increasedlumbar bone density in men; the results on femoral neck bonedensity are inconclusive. Without bone fracture data, the availabletrials offer weak and indirect inferences about the clinicalefficacy of testosterone on osteoporosis prevention and treatmentin men.
This article has been cited by other articles:
A. Liberati, D. G Altman, J. Tetzlaff, C. Mulrow, P. C Gotzsche, J. P A Ioannidis, M. Clarke, P J Devereaux, J. Kleijnen, and D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
BMJ,
December 4, 2009;
339(jul21_1):
b2700 - b2700.
[Abstract][Full Text][PDF]
G. Mazziotti, A. Giustina, E. Canalis, and J. P. Bilezikian Treatment of glucocorticoid-induced osteoporosis
Therapeutic Advances in Musculoskeletal Diseases,
October 1, 2009;
1(1):
27 - 34.
[Abstract][PDF]
A. Liberati, D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gotzsche, J. P.A. Ioannidis, M. Clarke, P. J. Devereaux, J. Kleijnen, and D. Moher The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Ann Intern Med,
August 18, 2009;
151(4):
W-65 - W-94.
[Abstract][Full Text][PDF]
E. P Weiss, K. Shah, L. Fontana, C. P Lambert, J. O Holloszy, and D. T Villareal Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone
Am. J. Clinical Nutrition,
May 1, 2009;
89(5):
1459 - 1467.
[Abstract][Full Text][PDF]
E. A. Jankowska, J. Jakubaszko, A. Cwynar, J. Majda, B. Ponikowska, D. Kustrzycka-Kratochwil, K. Reczuch, L. Borodulin-Nadzieja, W. Banasiak, P. A. Poole-Wilson, et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants
Eur J Heart Fail,
January 1, 2009;
11(1):
28 - 38.
[Abstract][Full Text][PDF]
J. F. Yarrow, C. F. Conover, A. V. Purandare, A. M. Bhakta, N. Zheng, B. Conrad, M. K. Altman, S. E. Franz, T. J. Wronski, and S. E. Borst Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats
Am J Physiol Endocrinol Metab,
November 1, 2008;
295(5):
E1213 - E1222.
[Abstract][Full Text][PDF]
G. Y. Gandhi, M. H. Murad, A. Fujiyoshi, R. J. Mullan, D. N. Flynn, M. B. Elamin, B. A. Swiglo, W. L. Isley, G. H. Guyatt, and V. M. Montori Patient-Important Outcomes in Registered Diabetes Trials
JAMA,
June 4, 2008;
299(21):
2543 - 2549.
[Abstract][Full Text][PDF]
B. A. Swiglo, M. H. Murad, H. J. Schunemann, R. Kunz, R. A. Vigersky, G. H. Guyatt, and V. M. Montori A Case for Clarity, Consistency, and Helpfulness: State-of-the-Art Clinical Practice Guidelines in Endocrinology Using the Grading of Recommendations, Assessment, Development, and Evaluation System
J. Clin. Endocrinol. Metab.,
March 1, 2008;
93(3):
666 - 673.
[Abstract][Full Text][PDF]
M. H. Emmelot-Vonk, H. J. J. Verhaar, H. R. Nakhai Pour, A. Aleman, T. M. T. W. Lock, J. L. H. R. Bosch, D. E. Grobbee, and Y. T. van der Schouw Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men: A Randomized Controlled Trial
JAMA,
January 2, 2008;
299(1):
39 - 52.
[Abstract][Full Text][PDF]
A. M. Isidori and A. Lenzi Testosterone Replacement Therapy: What We Know Is Not Yet Enough
Mayo Clin. Proc.,
January 1, 2007;
82(1):
11 - 13.
[Full Text][PDF]